OSR Health, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsOSR Health, Inc. is a global healthcare holding company with subsidiaries in South Korea and Switzerland developing oral T-cell immunotherapies, recombinant biologics, and neurovascular surgical devices.
What they do
OSR Health operates as a holding company with a hub-and-spoke model, supporting three portfolio companies: one focused on oral T-cell immunotherapies using a live attenuated bacterial vaccine strain (VXM01 platform), one on recombinant biologics for bone and cartilage regeneration, and one on neurovascular surgical devices. The company also holds an office in the U.S. and owns patent portfolios across its subsidiaries.
Revenue drivers
- Product sales (all segments) — Net sales totaled $2.9M in fiscal 2025, down from $3.5M in 2024. In Q2 2026, sales were $315,669, a 72% drop from the prior-year quarter.
- Cost of sales — Cost of sales was $229,065 in Q2 2026, yielding a gross profit of $86,605 (27.4% margin), up from $32,782 (2.9% margin) in Q2 2025.
- Other income — Other income of $1.59M in Q2 2026 offset operating losses, but is not a recurring revenue stream.
Recent performance
For the six months ended June 30, 2026, net sales were $799,727, down 58% from $1.90M in the same period of 2025. Operating loss improved to $3.03M in Q2 2026 from $5.23M in Q2 2025, but the company remains unprofitable. Net loss for fiscal 2025 was $27.1M, with operating cash flow of -$4.3M. Cash and equivalents were $1.5M as of June 30, 2026, against $166.6M in total assets and $124.9M in equity.
Strategy
Management aims to build a risk-diversified portfolio by acquiring or licensing assets from academia and industry, partnering with venture capital and private equity. The company encourages cooperation among subsidiaries and may seek liquidity through future sales of subsidiaries. In 2026, it launched a shareholder loyalty program distributing non-transferable CVRs that could grant up to 5 additional shares per share if closing-price thresholds of $2, $3, $4, and $5 are met over 12 months. It also entered into a binding term sheet for an exclusive global license of the VXM01 oral cancer immunotherapy platform from BCM Europe AG, its largest shareholder.
Risks
- Related-party conflicts — CEO serves as CEO of BCM Europe AG and board member of Vaximm AG, and the VXM01 license is a related-party transaction with non-standard economics, including a royalty pass-through to BCME.
- Nasdaq compliance — Company received a delisting notice or listing-rule failure in August 2026.
- Cash burn — Operating cash flow was -$4.3M in fiscal 2025, and cash reserves were only $1.5M as of June 30, 2026.
- Revenue decline — Quarterly sales fell to $315,669 in Q2 2026, a 72% year-over-year decline.
Outlook
Management has not provided specific forward guidance. The company is focusing on advancing its pipeline, including the VXM01 immunotherapy and recombinant biologic platform, while pursuing partnerships and fundraising. The shareholder loyalty program is intended to retain investors, but its execution depends on regulatory approval and Nasdaq requirements. The company continues to face uncertainty regarding its listing status and liquidity.